Dataset Information

Evolution of enhanced innate immune evasion by the SARS-CoV-2 B.1.1.7 UK variant

ABSTRACT: Here we use unbiased abundance proteomics and phosphoproteomics to assess global changes to host and viral proteins in Calu-3 cells at 10 and 24 hours post infection with either the B.1.1.7 UK variant or early-lineage SARS-CoV-2 viruses VIC and IC19.

INSTRUMENT(S): Orbitrap Exploris 480

ORGANISM(S): Homo Sapiens (human) Severe Acute Respiratory Syndrome Coronavirus 2

TISSUE(S): Lung, Epithelial Cell

SUBMITTER: Mehdi Bouhaddou

LAB HEAD: Nevan J. Krogan

PROVIDER: PXD026302 | Pride | 2022-01-20

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	20210302_115158_InfectionUK_ab_v2_nonorm_Report_PRIDE.csv	Csv
	20210404_211057_Infection_UK1_ph_wPTMloc_Report_wKeys_rmIC19rep2_PRIDE.csv	Csv
	SARS-CoV-2_FASTA_20200305.fasta	Fasta
	SARS-CoV-2_Orf1ab_trypticpeptides.fasta	Fasta
	SARS-CoV-2_variants_trypticpeptides.fasta	Fasta

Items per page:

1 - 5 of 71

Publications

Evolution of enhanced innate immune evasion by SARS-CoV-2.

Thorne Lucy G LG Bouhaddou Mehdi M Reuschl Ann-Kathrin AK Zuliani-Alvarez Lorena L Polacco Ben B Pelin Adrian A Batra Jyoti J Whelan Matthew V X MVX Hosmillo Myra M Fossati Andrea A Ragazzini Roberta R Jungreis Irwin I Ummadi Manisha M Rojc Ajda A Turner Jane J Bischof Marie L ML Obernier Kirsten K Braberg Hannes H Soucheray Margaret M Richards Alicia A Chen Kuei-Ho KH Harjai Bhavya B Memon Danish D Hiatt Joseph J Rosales Romel R McGovern Briana L BL Jahun Aminu A Fabius Jacqueline M JM White Kris K Goodfellow Ian G IG Takeuchi Yasu Y Bonfanti Paola P Shokat Kevan K Jura Natalia N Verba Klim K Noursadeghi Mahdad M Beltrao Pedro P Kellis Manolis M Swaney Danielle L DL García-Sastre Adolfo A Jolly Clare C Towers Greg J GJ Krogan Nevan J NJ

Nature 20211223 7897

The emergence of SARS-CoV-2 variants of concern suggests viral adaptation to enhance human-to-human transmission<sup>1,2</sup>. Although much effort has focused on the characterization of changes in the spike protein in variants of concern, mutations outside of spike are likely to contribute to adaptation. Here, using unbiased abundance proteomics, phosphoproteomics, RNA sequencing and viral replication assays, we show that isolates of the Alpha (B.1.1.7) variant<sup>3</sup> suppress innate immu ...[more]

PMID: 34942634

Similar Datasets

Project description:Influenza B virus (IBV) strains are one of the components of seasonal influenza vaccines in both trivalent and quadrivalent formulations. The vast majority of these vaccines are produced in embryonated chickens' eggs. While optimized backbones for vaccine production in eggs exist and are in use for influenza A viruses, no such backbones exist for IBVs, resulting in unpredictable production yields. To generate an optimal vaccine seed virus backbone, we have compiled a panel of 71 IBV strains from 1940 to present day, representing the known temporal and genetic variability of IBV circulating in humans. This panel contains strains from the B/Victoria/2/87-like lineage, B/Yamagata/16/88-like lineage and the ancestral lineage that preceded their split to provide a diverse set that would help to identify a suitable backbone which can be used in combination with hemagglutinin (HA) and neuraminidase (NA) glycoproteins from any IBV strain to be incorporated into the seasonal vaccine. We have characterized and ranked the growth profiles of the 71 IBV strains and the best performing strains were used for co-infection of eggs, followed by serial passaging to select for high-growth reassortant viruses. After serial passaging, we selected 10 clonal isolates based on their growth profiles assessed by hemagglutination and plaque-forming units. We then generated reverse genetics systems for the three clones that performed best in growth curves. The selected backbones were then used to generate different reassortant viruses with HA/NA combinations from high and low titer yielding wild type IBV. When the growth profiles of the recombinant reassortant viruses were tested, the low titer yielding HA/NA viruses with the selected backbones yielded higher titers similar to those from high titer yielding HA/NA combinations. The use of these IBV backbones with improved replication in eggs might increase yields for the influenza B virus components of seasonal influenza virus vaccines.